Verification evidence is still being completed.
PDF / print export
Aplagon
Helsinki, Finland
- Verified lead
- Aki Prihti
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Cardiovascular Therapeutics, Thromboinflammation, Vascular Occlusion, Clinical Development, and Biopharma
- Review cycle
- May 2026
- Full address
- Helsinki, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Aplagon material confirming the company is based in Helsinki, Finland.
- Editorial note
- Aplagon is published because official company materials confirm current leadership, Helsinki operating footprint, and a real cardiovascular therapeutics platform.
Cardiovascular Therapeutics, Thromboinflammation, Vascular Occlusion, Clinical Development, and Biopharma
Official leadership disclosure, Official Helsinki operating-footprint disclosure, Clinical-stage therapeutics platform claim
Aplagon is published because official company materials confirm current leadership, Helsinki operating footprint, and a real cardiovascular therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Helsinki, Finland
Aplagon
Cardiovascular Therapeutics, Thromboinflammation, Vascular Occlusion, Clinical Development, and Biopharma · Clinical-stage therapeutics platform
Aplagon runs cardiovascular drug development, clinical therapeutics programs, and biopharma platform development in Helsinki, Finland.
- Lead
- Aki Prihti (verified ↗)
- Address
- Helsinki, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Cardiovascular Drug Development · Clinical Therapeutics Programs · Biopharma Platform Development
- Founded
- 2009
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Aki Prihti
CEO
Full addressHelsinki, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Aplagon company materials stating the company is based in Helsinki, Finland.
Open sourceClinical-stage therapeutics platform
Helsinki, Finland. Cardiovascular Therapeutics, Thromboinflammation, Vascular Occlusion, Clinical Development, and Biopharma. Review completed on 22 Mar 2026.
Finnish corporate and clinical-development oversight
Official leadership disclosure, Official Helsinki operating-footprint disclosure, Clinical-stage therapeutics platform claim
Cardiovascular Therapeutics, Thromboinflammation, Vascular Occlusion, Clinical Development, and Biopharma
Aplagon is published because official company materials confirm current leadership, Helsinki operating footprint, and a real cardiovascular therapeutics platform.
Editorial note
Aplagon is published because official company materials confirm current leadership, Helsinki operating footprint, and a real cardiovascular therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cardiovascular Drug Development
Clinical Therapeutics Programs
Biopharma Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Cardiovascular R&D systems
Program management infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Aplagon located?
- Aplagon operates from Helsinki, Finland, Helsinki, Finland.
- Who runs Aplagon?
- Aplagon is led by Aki Prihti, CEO. Verified 22 Mar 2026.
- What does Aplagon do?
- Aplagon runs cardiovascular drug development, clinical therapeutics programs, and biopharma platform development in Helsinki, Finland. Core capabilities: Cardiovascular Drug Development, Clinical Therapeutics Programs, Biopharma Platform Development.
Editorial context
Related technical briefs
Briefs that name Helsinki as a covered market or city.